Loading…
Reported covered position: SR. DIR. GOVT. RELATIONS AND PUBLIC POLICY
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
S. 296, Preserving Access to Life Saving Medicines Act; H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act (ULTRA); Life Sciences Investment Act Issues relating to R&D funding for rare disease products, biosimilars and other products; end stage renal disease (ESRD) orphan drugs; reimbursements; drug shortages; DEA quotas; prescription drug user fees; exclusivity periods
American Middle Class Tax (AMT) Relief Act of 2007
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2011 · fourth_quarter · Q4
S. 296, Preserving Access to Life Saving Medicines Act; H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act (ULTRA); Life Sciences Investment Act Issues relating to R&D funding for rare disease products, biosimilars and other products; end stage renal disease (ESRD) orphan drugs; reimbursements; drug shortages; DEA quotas; prescription drug user fees; exclusivity periods
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
H.R. 3590, Patient Protection and Affordable Care Act H.R. 4872, Health Care and Education Reconciliation Act Issues related to biosimilar approval pathway, healthcare reform, orphan drugs, end stage renal disease bundling and non-injectable oral equivalents; state Medicare waiver and Elaprase
To suspend temporarily the duty on 1-Amino-2,6-dimethylbenzene.
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 3590, Patient Protection and Affordable Care Act H.R. 4872, Health Care and Education Reconciliation Act Issues related to biosimilar approval pathway, healthcare reform, orphan drugs, end stage renal disease bundling and non-injectable oral equivalents; state Medicare waiver and Elaprase
Promoting Innovation and Access to Life-Saving Medicine Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 1548, Pathway for Biosimilars Act, provisions relating to ultra-orphan biologics. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, provisions relating to ultra-orphan biologics. H.H. 3200, America's Affordable Health Choices Act of 2009.
Promoting Innovation and Access to Life-Saving Medicine Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 1548, Pathway for Biosimilars Act, provisions relating to ultra-orphan biologics. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, provisions relating to ultra-orphan biologics.
Promoting Innovation and Access to Life-Saving Medicine Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 1548, Pathway for Biosimilars Act, provisions relating to ultra-orphan biologics. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, provisions relating to ultra-orphan biologics. H.R. 3200, America's Affordable Health Choices Act of 2009.
Promoting Innovation and Access to Life-Saving Medicine Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 1548, Pathway for Biosimilars Act, H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act - provisions relating to ultra-orphan biologics; H.R. 3200, America's Affordable Health Choices Act of 2009; follow-on biologics; DEA quota
Promoting Innovation and Access to Life-Saving Medicine Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 1548, Pathway for Biosimilars Act, provisions relating to ultra-orphan biologics. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, provisions relating to ultra-orphan biologics.
Promoting Innovation and Access to Life-Saving Medicine Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 1548, Pathway for Biosimilars Act, H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act - provisions relating to ultra-orphan biologics; H.R. 3200, America's Affordable Health Choices Act of 2009; follow-on biologics; DEA quota
Pathway for Biosimilars Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 1548, Pathway for Biosimilars Act, H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act - provisions relating to ultra-orphan biologics; H.R. 3200, America's Affordable Health Choices Act of 2009; follow-on biologics; DEA quota
Pathway for Biosimilars Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 1548, Pathway for Biosimilars Act, provisions relating to ultra-orphan biologics. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, provisions relating to ultra-orphan biologics.
Pathway for Biosimilars Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 1548, Pathway for Biosimilars Act, provisions relating to ultra-orphan biologics. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, provisions relating to ultra-orphan biologics. H.H. 3200, America's Affordable Health Choices Act of 2009.
Pathway for Biosimilars Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 1548, Pathway for Biosimilars Act, H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act - provisions relating to ultra-orphan biologics; H.R. 3200, America's Affordable Health Choices Act of 2009; follow-on biologics; DEA quota
Pathway for Biosimilars Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 1548, Pathway for Biosimilars Act, provisions relating to ultra-orphan biologics. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, provisions relating to ultra-orphan biologics.
Pathway for Biosimilars Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 1548, Pathway for Biosimilars Act, provisions relating to ultra-orphan biologics. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, provisions relating to ultra-orphan biologics. H.R. 3200, America's Affordable Health Choices Act of 2009.
America's Affordable Health Choices Act of 2009
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 1548, Pathway for Biosimilars Act, provisions relating to ultra-orphan biologics. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, provisions relating to ultra-orphan biologics. H.R. 3200, America's Affordable Health Choices Act of 2009.
America's Affordable Health Choices Act of 2009
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 1548, Pathway for Biosimilars Act, H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act - provisions relating to ultra-orphan biologics; H.R. 3200, America's Affordable Health Choices Act of 2009; follow-on biologics; DEA quota
America's Affordable Health Choices Act of 2009
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 1548, Pathway for Biosimilars Act, H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act - provisions relating to ultra-orphan biologics; H.R. 3200, America's Affordable Health Choices Act of 2009; follow-on biologics; DEA quota
American Middle Class Tax (AMT) Relief Act of 2007
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 3590, Patient Protection and Affordable Care Act Health care reform, pathway for follow-on biologics, orphan drugs, DEA quota, end stage renal disease
Pathway for Biosimilars Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 5629, Pathway for Biosimilars Act. Education and policy issues, ultra-orphan biologics provision, follow-on biologics bill, home infusion, ESRD bundling issues, and PTSD study.
Pathway for Biosimilars Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 5629, Pathway for Biosimilars Act, provisions related to data exclusivity.
Pathway for Biosimilars Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 5629, Pathway for Biosimilars Act, provisions related to data exclusivity. Home infusion, ESRD bundling issues, PTSD study.
Pathway for Biosimilars Act
Client: SHIRE PHARMACEUTICALS LLC · Firm: SHIRE PHARMACEUTICALS LLC
H.R. 5629, Pathway for Biosimilars Act. Education and policy issues, ultra-orphan biologics provision, follow-on biologics bill, home infusion, ESRD bundling issues, and PTSD study.
2011 · third_quarter · Q3
ADHD awareness; R&D funding for rare disease products, biosimilars and other products; Life Sciences Investment Act
Life Sciences Investment Act; orphan drugs; end stage renal disease (ESRD) bundling of non-injectable oral equivalents; ESRD Quality Incentive program; Prescription Drug User Fee program; reimbursements; drug shortages; DEA quotas
Filing targets: SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2011 · second_quarter · Q2
ADHD awareness; R&D funding for rare disease products, biosimilars and other products; Life Sciences Investment Act
S. 296, Preserving Access to Life Saving Medicines Act; Life Sciences Investment Act; orphan drugs; end stage renal disease (ESRD) bundling of non-injectable oral equivalents; ESRD Quality Incentive program; Prescription Drug User Fee program; reimbursements; drug shortages; DEA quotas
Filing targets: SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2011 · first_quarter · Q1
Issues related to implementation of healthcare reform; ADHD awareness; R&D funding for rare disease products, biosimilars and other products; end stage renal disease (ESRD) bundling of non-injectable oral equivalents; ESRD Quaklity Incentive program; reimbursements; Prescription Drug User Fee program; S.606, Creating Hope Act of 2011; Life Sciences Investment Act
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2010 · fourth_quarter · Q4
Issues related to implementation of healthcare reform, ADHD awareness, orphan drugs and R&D funding, end stage renal disease bundling and non-injectable oral equivalents; reimbursements and comparative efffectiveness research
Filing targets: HOUSE OF REPRESENTATIVES
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2010 · third_quarter · Q3
Issues related to implementation of healthcare reform, ADHD awareness, orphan drugs and R&D funding, end stage renal disease bundling and non-injectable oral equivalents; reimbursements and comparative efffectiveness research
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2010 · third_quarter · Q3
End Stage Renal Disease (ESRD) bundling and non-injectable oral equivalents;
Issues related to biosimilar approval pathway, orphan drugs, end stage renal disease bundling and non-injectable oral equivalents
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2010 · second_quarter · Q2
End Stage Renal Disease (ESRD) bundling and non-injectable oral equivalents;
Issues related to biosimilar approval pathway, orphan drugs, end stage renal disease bundling and non-injectable oral equivalents
Filing targets: Executive Office of the President (EOP)
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2010 · first_quarter · Q1
H.R. 3590, Patient Protection and Affordable Care Act H.R. 4872, Health Care and Education Reconciliation Act Issues related to biosimilar approval pathway, healthcare reform, orphan drugs, end stage renal disease bundling and non-injectable oral equivalents; state Medicare waiver and Elaprase
End Stage Renal Disease (ESRD) bundling and non-injectable oral equivalents; State Medicare waiver and Elaprase
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2009 · fourth_quarter · Q4
H.R. 3590, Patient Protection and Affordable Care Act Health care reform, pathway for follow-on biologics, orphan drugs, DEA quota, end stage renal disease
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2009 · third_quarter · Q3
H.R. 1548, Pathway for Biosimilars Act, H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act - provisions relating to ultra-orphan biologics; H.R. 3200, America's Affordable Health Choices Act of 2009; follow-on biologics; DEA quota
H.R. 1548, Pathway for Biosimilars Act, H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act - provisions relating to ultra-orphan biologics; H.R. 3200, America's Affordable Health Choices Act of 2009; follow-on biologics; DEA quota
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2009 · second_quarter · Q2
H.R. 1548, Pathway for Biosimilars Act, provisions relating to ultra-orphan biologics. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, provisions relating to ultra-orphan biologics. H.R. 3200, America's Affordable Health Choices Act of 2009.
H.R. 1548, Pathway for Biosimilars Act, provisions relating to ultra-orphan biologics. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, provisions relating to ultra-orphan biologics. H.H. 3200, America's Affordable Health Choices Act of 2009.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2009 · first_quarter · Q1
H.R. 1548, Pathway for Biosimilars Act, provisions relating to ultra-orphan biologics. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, provisions relating to ultra-orphan biologics.
H.R. 1548, Pathway for Biosimilars Act, provisions relating to ultra-orphan biologics. H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, provisions relating to ultra-orphan biologics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2008 · fourth_quarter · Q4
Issues related to Medicare reimbursement, home infusion, ESRD bundling issues, PTSD study.
H.R. 5629, Pathway for Biosimilars Act. Education and policy issues, ultra-orphan biologics provision, follow-on biologics bill, home infusion, ESRD bundling issues, and PTSD study.
H.R. 5629, Pathway for Biosimilars Act. Education and policy issues, ultra-orphan biologics provision, follow-on biologics bill, home infusion, ESRD bundling issues, and PTSD study.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2008 · third_quarter · Q3
Issues related to Medicare reimbursement, home infusion, ESRD bundling issues, PTSD study.
H.R. 5629, Pathway for Biosimilars Act, provisions related to data exclusivity.
H.R. 5629, Pathway for Biosimilars Act, provisions related to data exclusivity. Home infusion, ESRD bundling issues, PTSD study.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2008 · second_quarter · Q2
Biosimilars legislation; orphan provisions; ADHD
Biosimilars legislation; orphan provisions; ADHD
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2008 · first_quarter · Q1
Biosimilars legislation; orphan provisions; ADHD Agency for Healthcare Research & Quality (Line 17)
Biosimilars legislation; orphan provisions; ADHD Agency for Healthcare Research & Quality (Line 17)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2007 · year_end · YY
Education & policy issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2007 · mid_year · RR
Educating and Policy Issues
Educating and Policy Issues
Educating and Policy Issues
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2007 · year_end · RR
Educating and Policy Issues
Educating and Policy Issues
Educating and Policy Issues
SHIRE PHARMACEUTICALS LLC via SHIRE PHARMACEUTICALS LLC
2007 · year_end · RR